Clofazamine for the Treatment of Mycobacterium Avium Intracellulare(MAI)
NCT00652067 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1
Last updated 2008-04-03
Summary
This protocol is an single patient IND to provide clofazamine to treat one patient who has MAI and is resistant to or can not tolerate standard of care. The drug is not otherwise available.
Conditions
- Infection, Mycobacterium Avium-Intracellulare
Sponsors & Collaborators
-
Yale University
lead OTHER
Principal Investigators
-
Margaret Pisani, M.D. · Yale University
Eligibility
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-05-31
- Primary Completion
- 2007-05-31
- Completion
- 2007-05-31
More Related Trials
-
Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants
NCT06106074 ·Status: COMPLETED ·Phase: PHASE1
-
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
NCT04549363 ·Status: TERMINATED ·Phase: PHASE3
-
Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis
NCT03906344 ·Status: NO_LONGER_AVAILABLE
-
Safety and Tolerability of LIM-0705 in Healthy Male Subjects
NCT01060475 ·Status: COMPLETED ·Phase: PHASE1
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
NCT04079179 ·Status: RECRUITING ·Phase: PHASE2
-
Moving Foward With Myeloma (MFM)
NCT07236502 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants
NCT05205447 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas
NCT06502171 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
NCT06987708 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
NCT00099047 ·Status: COMPLETED ·Phase: PHASE2
-
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
NCT02030964 ·Status: COMPLETED ·Phase: PHASE1
-
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
NCT00665067 ·Status: COMPLETED
-
Allogeneic BM-MSCs in Patients with Lumbar Facet Arthropathy
NCT04410731 ·Status: COMPLETED ·Phase: PHASE1
-
TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients
NCT06388759 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
NCT02425904 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Prevention of Treatment Induced Neuropathy in Multiple Myeloma
NCT01283997 ·Status: COMPLETED ·Phase: PHASE2
-
Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors
NCT05142371 ·Status: COMPLETED ·Phase: NA
-
Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides
NCT00002557 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II High-Dose Cyclophosphamide for Multiple Sclerosis
NCT00296205 ·Status: WITHDRAWN ·Phase: PHASE2
-
Ph II Study of Azacitidine in Myelofibrosis
NCT00569660 ·Status: COMPLETED ·Phase: PHASE2
-
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
NCT02839720 ·Status: COMPLETED ·Phase: PHASE2
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
NCT07281781 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma
NCT02157636 ·Status: COMPLETED ·Phase: PHASE1
-
Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients
NCT00489372 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
NCT04924608 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3